Co-targeting CD47 and VEGF elicited potent anti-tumor effects in gastric cancer
ConclusionsOur preclinical studies collectively offer substantiation that CD47 holds promise as a prospective target for gastric cancer, while also highlighting the potential of anti-angiogenic therapy to enhance tumor responsiveness to anti-CD47 immunotherapy.
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research
More News: Allergy & Immunology | Cancer | Cancer & Oncology | Gastric (Stomach) Cancer | Gastroenterology | Hematology | Immunotherapy | Study